Search results for "Plasmin"

showing 10 items of 176 documents

Associations between leprosy and serum protein groups

1970

Serum protein group typings were done on a sample of n=173 adult healthy Negroes from the Macua tribe in Mozambique and on n=129 leprous individuals from the same tribe. Unfortunately, the type of leprosy is not known. Whilst between leprosy and haptoglobins, transferrins and Pi proteins no associations could be observed, statistically significant associations between leprosy and ceruloplasmin resp. β2 I were found. It is pointed out that these associations should be confirmed by further research on other populations and with respect to type and process of leprosy, until biological and population genetical interpretations will be possible.

AdultMalePopulationSerum proteinBlack PeopleTribe (biology)LeprosyGeneticsmedicineHumansAlleleMetabolic diseaseeducationAllelesMozambiqueGenetics (clinical)Glycoproteinseducation.field_of_studyHaptoglobinsbiologyHaptoglobinTransferrinCeruloplasminfood and beveragesmedicine.diseaseBlack or African AmericanGenetics PopulationPhenotypeImmunologyBlood Group Antigensbiology.proteinFemaleLeprosyTrypsin InhibitorsCeruloplasminHuman Genetics
researchProduct

Chronic occupational noise exposure: Effects on DNA damage, blood pressure, and serum biochemistry

2019

Abstract Noise levels experienced by industrial workers may cause both auditory and non-auditory harmful effects. We have studied the effects of chronic industrial noise exposure on DNA damage, blood pressure, and serum biochemistry in factory workers. Male workers (109 individuals) in three parts of a food factory in Shahroud, Iran were enrolled as the exposed group and male office workers (123 individuals) were the unexposed control group. Noise exposure was measured (dosimetry) and the comet assay was used to evaluate DNA damage in peripheral blood mononuclear cells. Glutathione peroxidase (GPx) and ceruloplasmin (Cp) levels were measured in serum samples. GPx levels, systolic and diasto…

AdultMaleSerum0301 basic medicineDNA damageHealth Toxicology and MutagenesisPhysiologyBlood PressureIran010501 environmental sciencesmedicine.disease_cause01 natural sciencesPeripheral blood mononuclear cellYoung Adult03 medical and health scienceschemistry.chemical_compoundOccupational ExposureGeneticsmedicineHumansIndustry0105 earth and related environmental scienceschemistry.chemical_classificationGlutathione Peroxidasebiologybusiness.industryGlutathione peroxidaseCeruloplasminGlutathioneMiddle AgedComet assay030104 developmental biologyBlood pressurechemistryLeukocytes MononuclearNoise Occupationalbiology.proteinComet AssayCeruloplasminbusinessOxidative stressDNA DamageMutation Research/Genetic Toxicology and Environmental Mutagenesis
researchProduct

Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys

2009

In a subgroup of hereditary angioedema (HAE) patients with normal C1-esterase inhibitor levels, HAE is caused by a Thr309Lys mutation in the coagulation factor XII (F12) gene. The aim of this study was to examine elements of the kallikrein-kinin system ('contact system') and the downstream-linked coagulation, complement and fibrinolytic systems in the plasma of six patients with HAE caused by the Thr309Lys mutation and healthy probands. Blood samples were taken from participants during the symptom-free interval between attacks. Samples were analyzed for activity and concentrations of components of the kallikrein-kinin system and linked enzyme systems. The mean FXII clotting activity was 90%…

AdultMalemedicine.medical_specialtyAdolescentMutation MissenseKininsCoagulation Factor XIIFactor XIIaGene mutationYoung AdultInternal medicinemedicineHumansPoint MutationHereditary Angioedema Type IIIComplement Pathway ClassicalAgedAged 80 and overFactor XIIAngioedemaChemistryFibrinolysisDextran SulfateAngioedemas HereditaryPrekallikreinPrekallikreinBlood ProteinsHematologyGeneral MedicineMiddle AgedSilicon Dioxidemedicine.diseaseEnzyme ActivationEndocrinologyAmino Acid SubstitutionChromogenic CompoundsCoagulationTissue Plasminogen ActivatorHereditary angioedemaImmunologyFemaleKallikreinsmedicine.symptomcirculatory and respiratory physiologyBlood Coagulation & Fibrinolysis
researchProduct

Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina

1991

PAI-1 antigen, tPA antigen and thrombin - antithrombin III complexes (TAT) levels were measured in 10 males with stable angina and type-II diabetes mellitus and in 16 males with stable angina without diabetes or other risk factors (hyperfibrinogenaemia, hyperlipidaemia, diabetes, hypertension, smoking and obesity) known to increase PAI levels. Ten healthy men of equivalent age served as controls. Because only diabetics with coronary artery disease (CAD) showed a decreased fibrinolytic capacity, a second study was performed on the 16 non-diabetic CAD patients to determine whether submaximal workload induces significant changes of tPA and PAI levels. TAT levels were increased in CAD, and sign…

AdultMalemedicine.medical_specialtyAntithrombin IIICoronary DiseaseStable anginaAngina PectorisFibrin Fibrinogen Degradation ProductsCoronary artery diseaseThrombinAntigenDiabetes mellitusInternal medicinemedicineHumanscardiovascular diseasesAgedbusiness.industryFibrinolysisPlasminogen activator inhibitor antigenAntithrombinFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseObesityPlasminogen InactivatorsEndocrinologyDiabetes Mellitus Type 2Tissue Plasminogen ActivatorExercise TestbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease.

1998

Abstract —A family history of ischemic events is a major determinant of coronary artery disease (CAD). Plasma levels of plasminogen activator inhibitor 1 (PAI-1) modulate this risk. A deletion/insertion polymorphism within the PAI-1 locus (4G/5G) affects the expression of this gene. We investigated the relationship between the PAI-1 4G/5G polymorphism in 1179 healthy employees of our institution and the occurrence of CAD in their first-degree relatives. A family history of documented ischemic coronary disease was assessed by a modified WHO questionnaire. The PAI-1 4G/5G polymorphism was evaluated by polymerase chain reaction and endonuclease digestion. The group with a first-degree relativ…

AdultMalemedicine.medical_specialtyCoronary DiseaseLocus (genetics)BiologyGastroenterologyMedical RecordsGenetic determinismCohort StudiesCoronary artery diseasechemistry.chemical_compoundRisk FactorsInternal medicinePlasminogen Activator Inhibitor 1medicineHumansFamily historyAlleleAgedGeneticsPolymorphism GeneticChromosome MappingOdds ratioMiddle Agedmedicine.diseasechemistryPlasminogen activator inhibitor-1Regression AnalysisFemaleCardiology and Cardiovascular MedicineBody mass index
researchProduct

Hereditary angioedema with normal C1-INH withversuswithout specificF12gene mutations

2015

Background Hereditary angioedema with normal C1-INH may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or mutations in genes that are still unknown (HAE-unknown). To assess the differences in transmission and inheritance, clinical features, and laboratory parameters between patients with HAE-FXII and HAE-unknown. Methods Sixty-nine patients with HAE-FXII from 23 unrelated families and 196 patients with HAE-unknown from 65 unrelated families were studied. Results Both HAE-FXII and HAE-unknown are inherited as autosomal-dominant traits with incomplete penetrance. The male to female ratio was 1 : 68 in HAE-FXII and 1 : 6.3 in HAE-unknown. The maternal to pa…

AdultMalemedicine.medical_specialtyDatabases FactualOffspringImmunologyGene mutationSeverity of Illness IndexCohort StudiesYoung Adultchemistry.chemical_compoundAge DistributionInternal medicineHumansImmunology and AllergyMedicineHereditary Angioedema Type IIIAge of OnsetSex DistributionRetrospective Studiesmedicine.diagnostic_testAngioedemabusiness.industryIncidenceAngioedemas HereditaryMiddle AgedPrognosismedicine.diseasePenetranceRecombinant ProteinsPedigreePhenotypeEndocrinologychemistryPlasminogen activator inhibitor-1Factor XIIMutationHereditary angioedemaFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinPartial thromboplastin timeAllergy
researchProduct

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1993

We have measured various fibrinolytic and coagulation parameters (t-PA antigen, PAI, fibrinogen, plasminogen and factor VII) before and after 10 min of venous occlusion in 20 hypertryglyceridaemic subjects (twelve males and eight females, age 38 +/- 4 years, body mass index 23 +/- 1.5) and 20 healthy normal subjects, matched for sex (twelve males and eight females), age (37 +/- 3.5 years) and body mass index (22.8 +/- 1.4). At rest, t-PA:Ag, PAI, fibrinogen, plasminogen and factor VII were significantly (P < 0.005) higher in hypertriglyceridaemic subjects than in normal controls. After venous occlusion, the increase in all parameters except t-PA:Ag was more marked in the patient group than …

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentFibrinogenHyperlipoproteinemia Type IVVeinschemistry.chemical_compoundAntigenInternal medicineOcclusionFibrinolysisPlasminogen Activator Inhibitor 1medicineHumansFactor VIIbusiness.industryFibrinolysisHypertriglyceridemiaFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseConstrictionLipidsEndocrinologyApolipoproteinsCoagulationchemistryTissue Plasminogen ActivatorFemalebusinessBody mass indexmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

An unusual presentation of massive pulmonary embolism mimicking septal acute myocardial inferction treated with tenecteplase

2007

A 31-year-old man (175 cm, 82 kg) was referred to the emergency department 2 h after the sudden onset of acute dyspnea. Immediate ECG showed sinus tachycardia with ST elevations from V1 through V2 and a diagnosis of septal acute myocardial infarction was made. ECG on admission to the cardiology department showed the same results plus the S1-Q3-T3 pattern. Echocardiogram revealed a normally contracting left ventricle, a distended right ventricle with free wall hypokinesia and displacement of the interventricular septum towards the left ventricle. Thrombolytic therapy with tenecteplase 8000 IU and heparin 5000 IU was administered 5-10 min after hospitalisation and the patient was haemodynamic…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaSinus tachycardiaMyocardial InfarctionTenecteplaseDiagnosis DifferentialElectrocardiographyFibrinolytic AgentsInternal medicinemedicineHumansThrombolytic Therapycardiovascular diseasesMyocardial infarctionInterventricular septumtenecteplasebusiness.industrymassive pulmonary embolismElectrocardiography in myocardial infarctionHematologymedicine.diseasePulmonary embolismmedicine.anatomical_structureVentricleTissue Plasminogen ActivatorCardiologySeptum of BrainRadiologyMyocardial infarction diagnosismedicine.symptomCardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Postoperative Reduction of Fibrinolysis as a Prognostic Factor of Fatal Outcome

2001

For the resection of an esophagus carcinoma a mortality rate of 2 to 30% was described, It is still unclear whether an abdominothoracic or transhiatal intervention is superior regarding the outcome. To investigate the prognostic value of fibrinolytic markers, plasmin-α2-antiplasmin (PAP) and D-dimer (DD) values were determined daily in the early postoperative period for 11days. In addition, the course of PAP and DD concentrations was compared with the method of esophagectomy. Of the 28 patients enclosed in the study, 5 died between day 10 and day 34 owing to adult respiratory distress syndrome and septicemia. The PAP and DD concentrations increased in survivors after surgery until day 5 an…

AdultMalemedicine.medical_specialtyTime FactorsFatal outcomeEsophageal Neoplasmsmedicine.medical_treatmentReference range030204 cardiovascular system & hematologySensitivity and SpecificityGastroenterologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineFibrinolysisD-dimermedicineHumansFibrinolysinPostoperative PeriodSurvival rateAgedalpha-2-AntiplasminRespiratory distressbusiness.industryFibrinolysisMortality rateHematologyGeneral MedicineMiddle AgedPrognosisAntifibrinolytic AgentsSurgeryEsophagectomySurvival RateROC CurveEsophagectomyFemalebusinessBiomarkers030215 immunologyClinical and Applied Thrombosis/Hemostasis
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct